Intense pulsed light (IPL) technology has the potential to revolutionize dry eye management and ocular surface disease.
Halting glaucoma progression can be challenging, but as it turns out, medication is not the only tool in an OD’s toolbox. Many factors influence glaucoma progression in patients, some of which may be unrelated to the disease itself.
Ocular surface inflammation may sound simple and specific but actually encompasses more than meets the eye.
Dry eye disease (DED) is far from being a single disease. Rather, it encompasses many different entities.
Technology and innovation has improved many aspects of health care and eye care, including ocular aesthetics.
Manufacturers’ global revenues for dry eye treatments is expected to top $6 billion in 2023.